Postoperative ileus Market: Epidemiology, Therapies, Companies, DelveInsight | Palisade Bio, Merck

Postoperative ileus emerging therapies, such as LB1148, and others, are expected to boost the Postoperative ileus Market in the upcoming years.

DelveInsight has launched a new report on "Postoperative ileus - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Postoperative ileus, historical and forecasted epidemiology as well as the Postoperative ileus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Postoperative ileus market report @ https://www.delveinsight.com/report-store/postoperative-ileus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Postoperative ileus Market Report:

The global market for Postoperative Ileus (POI) treatment is projected to experience steady growth over the forecast period from 2024 to 2034, driven by a consistent compound annual growth rate (CAGR). The increasing prevalence of POI is closely tied to the rising number of surgical procedures, especially abdominal surgeries. Contributing factors include an aging global population, a higher incidence of chronic diseases that require surgical treatment, and advancements in surgical techniques that have led to more complex procedures.
While only a few pharmaceutical companies are currently addressing the challenges associated with POI, some treatments are already in use. These include **Entereg (alvimopan)** by **Merck & Co.** and **RELISTOR (methylnaltrexone)** by **Valeant Pharmaceuticals**. Additionally, new therapies are emerging in clinical development, such as **LB1148** from **Palisade Bio** and **ORE001** from **Orexa BV**, both of which have shown encouraging results in enhancing recovery after surgery. These novel treatments hold promise for improving patient recovery, lowering healthcare expenses, and raising the overall quality of postoperative care.
Analysis shows that around **22 million inpatient surgeries** are performed annually in the U.S., with about **2.7 million cases** resulting in **Postoperative Ileus (POI)** lasting several days.
A review of over 800,000 U.S. surgical cases using ICD-9 codes found a **4.3% overall rate** of ileus. POI was seen in **15-20% of abdominal surgeries**, **6-10% of colon surgeries**, and **10% of cardiac or orthopedic procedures**. In a study of 38,068 patients, the **overall POI incidence was 10.3%**, with rates of **20.6% (open) vs. 14.6% (laparoscopic) colectomy**, and **11.6% (open) vs. 3.2% (laparoscopic) cholecystectomy**.
Key Postoperative ileus companies such as Palisade Bio, Merck, and others are evaluating new drugs for Postoperative ileus to improve the treatment landscape.
Promising Postoperative ileus therapies includeLB1148, ENTEREG (alvimopan), and others.

Postoperative ileus Overview

Postoperative Ileus (POI) is a condition characterized by reduced or impaired gastrointestinal (GI) motility following abdominal or non-abdominal surgery. GI motility involves the coordinated movement of food through the digestive tract-from the mouth, down the throat and esophagus, through the stomach and intestines, and ultimately out of the body.

A diagnosis of POI is typically made when two or more of the following symptoms persist without improvement by the fourth day after surgery: (a) nausea and vomiting, (b) inability to consume food orally for at least 24 hours, (c) lack of gas passage for 24 hours, (d) abdominal bloating or distension, and (e) imaging findings indicating ileus.

POI is a significant concern for surgeons, as it can lead to longer hospital stays, increased healthcare costs, and higher rates of postoperative complications. Risk factors commonly associated with POI include being male, older age, and experiencing substantial blood loss during surgery. Although advances in understanding the underlying mechanisms of POI have led to improved prevention and treatment strategies, it still affects approximately 10-30% of patients undergoing abdominal surgery.

Postoperative ileus Market Outlook

The Postoperative Ileus (POI) treatment market is projected to grow steadily over the next decade, driven by the rising volume of surgical procedures, particularly abdominal surgeries, and the growing need for effective postoperative recovery solutions. As healthcare systems aim to reduce hospital stays, minimize complications, and improve patient outcomes, the demand for advanced POI therapies is expected to increase significantly.

Discover how the Postoperative ileus market is rising in the coming years @ https://www.delveinsight.com/sample-request/postoperative-ileus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Marketed Postoperative Ileus (POI) Drugs
ENTEREG (alvimopan): Merck
Postoperative ileus Emerging Drugs
LB1148: Palisade Bio

Scope of the Postoperative ileus Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Postoperative ileus Companies: Palisade Bio, Merck, and others
Key Postoperative ileus Therapies: LB1148, ENTEREG (alvimopan), and others
Postoperative ileus Therapeutic Assessment: Postoperative ileus current marketed and Postoperative ileus emerging therapies
Postoperative ileus Market Dynamics: Postoperative ileus market drivers and Postoperative ileus market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Postoperative ileus Unmet Needs, KOL's views, Analyst's views, Postoperative ileus Market Access and Reimbursement

To know what's more in our Postoperative ileus report, visit https://www.delveinsight.com/report-store/postoperative-ileus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Postoperative ileus Market Report:
Postoperative ileus market report covers a descriptive overview and comprehensive insight of the Postoperative ileus Epidemiology and Postoperative ileus market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Postoperative ileus market report provides insights into the current and emerging therapies.
The Postoperative ileus market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Postoperative ileus market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Postoperative ileus market.

Got queries? Click here to know more about the Postoperative ileus market Landscape https://www.delveinsight.com/sample-request/postoperative-ileus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Postoperative ileus Patient Share (%) Overview at a Glance
5. Postoperative ileus Market Overview at a Glance
6. Postoperative ileus Disease Background and Overview
7. Postoperative ileus Epidemiology and Patient Population
8. Country-Specific Patient Population of Postoperative ileus
9. Postoperative ileus Current Treatment and Medical Practices
10. Unmet Needs
11. Postoperative ileus Emerging Therapies
12. Postoperative ileus Market Outlook
13. Country-Wise Postoperative ileus Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Postoperative ileus Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Postoperative ileus Market Outlook 2034 https://www.delveinsight.com/report-store/postoperative-ileus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Postoperative ileus Pipeline Insights, DelveInsight

"Postoperative ileus Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Postoperative ileus market. A detailed picture of the Postoperative ileus pipeline landscape is provided, which includes the disease overview and Postoperative ileus treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.